# Original Article

# The impact of IncRNA MG3 on laryngeal cancer cell growth, cycle, and apoptosis related factors

Yuan Li<sup>1\*</sup>, Xuehua Zhou<sup>1</sup>, Chenjuan Tao<sup>2\*</sup>, Chaohui Chen<sup>1</sup>, Caixia Cui<sup>1</sup>, Lili Dai<sup>1</sup>, Honglin Wu<sup>1</sup>, Qingyu Wei<sup>1</sup>, Song Luo<sup>1</sup>

<sup>1</sup>Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China; <sup>2</sup>Department of Neurology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China. \*Equal contributors.

Received February 21, 2017; Accepted April 13, 2017; Epub July 1, 2017; Published July 15, 2017

Abstract: Laryngeal cancer is a common head and neck malignant tumor. Long non-coding RNA (IncRNA) is a kind of RNA at the length more than 200 nucleotides that cannot code protein. They widely exist in the human genome. Maternally expressed gene 3 (MG3) is a kind of IncRNA that is associated with various malignant tumors development. This study explores the influence of MG3 on laryngeal cancer Hep-2 cell growth, cycle, and apoptosis related factors. Hep2 cells transfected by MG3 were treated as experimental group, while untransfected Hep2 cells were treated as control. MG3 expression was tested by real time PCR. Cell proliferation was evaluated by MTT assay. Cell cycle was determined by flow cytometry. Bcl-2, Bax, and survivin protein levels were detected by Western blot. MG3 expression significantly increased in Hep2 cells compared with control (P < 0.05). Hep2 cell OD value and cell percentage in S phase were obviously declined, while cell apoptosis were markedly enhanced (P < 0.05). OD value and cell percentage in S phase apparently reduced in 12 h, 24 h, and 48 h from experimental group (P < 0.05). Bcl-2 and survivin protein downregulated, while Bax protein elevated in experimental group following time extension (P < 0.05). MG3 overexpression inhibited laryngeal cancer Hep2 cell proliferation and arrested cell cycle with time dependence, which may achieve by suppressing Bcl-2 and survivin protein, and facilitating Bax protein expression.

Keywords: MG3, laryngeal cancer, proliferation, cell cycle, Bcl-2, surviving, Bax

#### Introduction

As a common type of head and neck malignant tumor in medical oncology, laryngeal cancer accounts for about 5.7-7.6% among various malignant tumors. Laryngeal cancer can be divided into three main types according to pathogenic site, such as supraglottic type, glottis type, and subglottic type. Its major pathologic type is squamous cell carcinoma [1]. Surgery, radiotherapy, chemotherapy, and gene therapy are the main forms of treatment for laryngeal cancer. Laryngeal cancer in early stage can be cured by surgery or radiochemotherapy. On the contrary, the curative effect and quality of life in patients with advanced laryngeal cancer is significantly reduced [2]. At the genetic level, there are numerous modes of human genome transcription. Only 2% of genes transcribe into proteins, whereas 98% of genes may become noncoding RNA (ncRNA) [3]. Most of ncRNAs are long non-coding RNAs (IncRNAs) at the length of longer than 200 amino acids, which mainly exist in the nucleus and cytoplasm of eukaryotes. Instead of protein coding, IncRNAs can only participate in biological processes at genetic, transcription, and posttranscription levels [4, 5]. Maternally expressed gene 3 (MG3) is a kind of IncRNA expressed in the brain, bone marrow, breast, uterus, lung, and gastrointestinal tract. MG3 is found expression deletion in multiple malignant tumors [6]. MG3 downregulation may involve in gastric cancer growth, proliferation, and apoptosis [7]. However, MG3 expression in laryngeal cancer and impact on cell proliferation and cell cycle are still unclear. This study aimed to investigate the impact of IncRNA MG3 on larvngeal cancer cell growth, cycle, and apoptosis related factors by transfecting MG3 to Hep2 cells.

Table 1. Primer sequences

Gene		Sequences (5'-3')
MG3	Forward	5'-AGCCGTCAAGAGCAATAACGAA-3'
	Reverse	5'-GTGCAGGGTCCGAGGT-3'
U6	Forward	5'-CTCGCTTCGGCAGCACA-3'
	Reverse	5'-AACGCTTCACGAATTTGCGT-3'

#### Materials and methods

#### Cells and reagents

Laryngeal cancer Hep-2 cells were obtained from Chinese Academy of Medical Sciences Institute of Basic Medical Sciences. MTT was purchased from Sigma (USA). Fetal bovine serum was bought from Sijiqing (Hangzhou, China). Annexin V-PE apoptosis detection kit was derived from Sigma (USA). Rabbit anti human Bcl-2, Bax, and survivin polyclonal antibodies, and HRP labeled goat anti rabbit IgG secondary antibody were got from ZSbio (Beijing, China). Rabbit anti human  $\beta$ -actin monoclonal antibody was purchased from Sigma (USA).

#### Routine cell culture

Hep2 cells were cultured in DMEM medium containing 10% FBS and maintained at 5% CO $_2$  and 37°C. The cells were digested by 0.25% trypsin and seeded in 24-well plate at  $10^5$ /L.


#### Grouping

Experimental group: Hep-2 cells in logarithmic phase were seeded in 6-well plate at  $1\times10^4$ /ml. MG3 vector was transfected to Hep-2 cells using lipofectamine 2000 when the cell fusion reached 60%. The cells were further cultured for 48 h after fluid change.

Control group: Hep-2 cells cultured in RPMI-1640 medium containing 10% FBS.

#### Real-time PCR

Trizol was used to extract total RNA from Hep2 cells. The cells were then added with 0.2 ml chloroform at room temperature for 3 min. Next, the supernatant was added with 0.5 ml isopropanol at room temperature for 10 min. After centrifuged to remove the supernatant, the RNA was washed by 75% ethanol and dissolved in 40  $\mu$ l DEPC water. Total RNA was



**Figure 1.** MG3 expression in Hep-2 cells. RNA was isolated from Hep-2 cells transfected with MG3 vector after culture for 12 h, 24 h and 48 h followed by measuring MG3 mRNA expression by RT-PCR. \*P < 0.05, compared with control. #P < 0.05, compared with 12 h. &P < 0.05, compared with 24 h.

reverse transcribed to cDNA by synthesizing poly A tail. cDNA was used as template for PCR amplification. The primer sequences were listed **Table 1**. The PCR reaction was composed of 95°C predegeneration for 5 min, followed by 30 cycles of 95°C degeneration for 30 s, 58°C annealing for 30 s, and 72°C elongation for 30 s, and 72°C for 10 min at last.

#### MTT assay


Hep-2 cells in logarithmic phase were seeded at  $8\times10^4$ /well for 12 h, 24 h, and 48 h, respectively. Then the cells were added with 20  $\mu$ I MTT solution at 5 mg/ml for 4 h. Next, the cells were treated by 150  $\mu$ I DMSO for 10 min and measured at 570 nm on microplate reader. The growth curve was drawn upon OD value and time.

#### Annexin V/PI detection

Hep-2 cells were collected at 48 h after MG3 transfection and added with FITC labeled Annexin V at 4°C for 10 min. Then the cells were added with 5  $\mu$ g/ml PI for 2 min. At last, the cells were resuspended in buffer and analyzed on flow cytometry.

#### Cell cycle analysis

Hep-2 cells were digested and centrifuged at 1000 r/min for 5 min. Next, the cells were collected in centrifuge tube at 1×10°/L and fixed in 75% ice ethanol for 12 h. At last, the cells were stained by PI avoid of light at 4°C for 30 min and analyzed on flow cytometry.



**Figure 2.** Hep-2 cell proliferation. After transfected with MG3 vector, proliferation of Hep-2 cell was measured by MTT assay. \*P < 0.05, compared with control. #P < 0.05, compared with 12 h. &P < 0.05, compared with 24 h.

#### Western blot

The cells were lysed by RIPA containing 0.1 mg/ml PMSF, aprotinin, and phosphatase inhibitor and centrifuged at 4°C and 12000 rpm for 30 min. The protein was added with loading buffer and boiled at 100°C for 5 min. Total protein was separated by 10% SDS-PAGE and transferred to PVDF membrane. After washed by TBST, the membrane was blocked at 4°C overnight. Next, the membrane was incubated in primary antibody (1:100) at 37°C for 2 h and secondary antibody at room temperature for 1 h. At last, the membrane was scanned and analyzed by Alphamager TM 2200 software to calculate the relative expression.


#### Statistical analysis

All data analyses were performed on SPSS 17.0 software. Enumeration data were compared by chi-square test, while measurement data were depicted as mean  $\pm$  standard deviation and evaluated by ANOVA. P < 0.05 was considered as statistical significance.

#### Results

#### MG3 expression in Hep-2 cells

We applied RT-PCR to detect MG3 expression in Hep-2 cells. Compared with control, MG3 expression significantly increased in Hep-2 cells from experimental group (P < 0.05). MG3 level gradually elevated in Hep-2 cells following time extension (P < 0.05) (**Figure 1**).



**Figure 3.** Hep-2 cell apoptosis after 48 h. Apoptosis of Hep-2 cells was measured by flow cytometry using PI and Annexin-V staining.

## Hep-2 cell proliferation comparison

We adopted MTT assay to compare Hep-2 cell proliferation. It was showed that Hep-2 cell OD value significantly declined in experimental group compared with control following time extension (P < 0.05) (Figure 2).

#### Hep-2 cell apoptosis comparison

Hep-2 cell apoptosis obviously enhanced in experimental group compared with control (Figure 3).

#### Hep-2 cell cycle comparison

It was found that cell percentage in S phase markedly reduced in 12 h, 24 h, and 48 h from experimental group compared with control (P < 0.05). Its proportion in S phase kept decreasing following time expansion (P < 0.05) (**Figure 4**).

BcI-2, Bax, survivin protein expression in Hep-2 cells

Bcl-2 and survivin protein downregulated, while Bax protein elevated in experimental group following time extension (P < 0.05) (**Figures 5, 6**).

#### Discussion

LncRNA is a kind of RNA with transcript longer than 200 nt. It locates in the nucleus or cytoplasm without protein coding function [8]. In recent years, it was showed that lncRNAs participate in regulating gene expression at multiple levels, such as X chromosome silence, genomic imprinting, and chromatin modification, transcription activation, nuclear transport [9]. LncRNAs participate in the process of cell apoptosis and cell cycle. Their abnormal expressions may induce various diseases, especially






Figure 4. Cell cycle changes in Hep-2 cells. After transfected with MG3 vector, cell cycle of Hep-2 cell was measured by flow cytometry. \*P < 0.05, compared with control. #P < 0.05, compared with 12 h. &P < 0.05, compared with 24 h.





cancer [10]. MG3 is a kind of IncRNA that inhibits cell proliferation and promotes apoptosis [11]. This study selected laryngeal cancer Hep-2 cells to explore the influence of MG3 on laryngeal cancer cell growth, cycle, and apoptosis related factors.


This study transfected MG3 to Hep-2 cells and observed MG3 level increased in experimental group following time extension. It suggested successful MG3 transfection. Previous study revealed that as an IncRNA coded by imprinted gene, MG3 was obviously expressed in embryonic development and a variety of normal cells. However, it was found declined or deleted in multiple tumors, such as hypophysoma, hepatocellular carcinoma, and ovarian cancer [12, 13].

Hep2 cell OD value was obviously declined in experimental group following time expansion, while cell apoptosis was markedly enhanced after 48 h. It indicated that MG3 overexpression suppressed Hep-2 cell proliferation. Regulation of p53 can affect non-small cell lung cancer cell proliferation and apoptosis


[14]. MG3 downregulation was found correlated with poor prognosis of gastric cancer [15]. This was similar with our results.


The most obvious characteristics of tumor cells are incessant cell division and proliferation. Cell cycle out of control plays a crucial role in malignant tumor, presenting as cell cycle disorders, cell proliferation enhancement, and apoptosis reduced [16]. Dysregulation of checkpoint for G1/S and G2/M phases may lead to abnormal cell proliferation, resulting in the occurrence of malignant tumor [17]. It was found that cell percentage in S phase markedly reduced in 12 h, 24 h, and 48 h from experimental group compared with control. Its proportion in S phase kept decreasing following time expansion. It suggested that MG3 overexpression can increase Hep-2 cell proportion in G1 phase and reduce cell proportion in S phase, leading to G1/S phase arrest. It indicated that MG3 can inhibit tumor growth and proliferation by regulating cell cycle with time dependence.


A variety of studies confirmed that cell apoptosis may cause cell death or lost. It was observed



**Figure 5.** Bcl-2, Bax, survivin mRNA expressions in Hep-2 cells. RNA was isolated from Hep-2 cells followed by measuring mRNA expression of Bcl-2, Bax and Survivin by RT-PCR. \*P < 0.05, compared with control. #P < 0.05, compared with 12 h. &P < 0.05, compared with 24 h.







**Figure 6.** Bcl-2, Bax, survivin protein expressions in Hep-2 cells. Protein was isolated from Hep-2 cells for analysis of the expression of Bcl-2, Bax and Survivin by western blot.

that multiple genes play critical roles in cell apoptosis, including pro-apoptotic genes and anti-apoptotic genes [18]. We used Western blot to test Bcl-2, Bax, and survivin protein expressions in Hep-2 cells. Bcl-2 and survivin protein downregulated, while Bax protein elevated in experimental group following time extension. Caspase-3 participates in cell apoptosis induced by various factors, thus is the most important apoptosis effect protein [19]. Bcl-2 can prolong cell survival, thus plays an inhibitory role on cell apoptosis without affecting cell division [20]. Bax may induce cell apoptosis via downregulating Bcl-2 [21]. It suggested that MG3 promoted cell apoptosis by suppressing Bcl-2 and survivin protein, and facilitating Bax protein expression.

#### Conclusion

MG3 overexpression inhibited laryngeal cancer Hep2 cell proliferation and arrested cell cycle with time dependence, which may achieve by suppressing Bcl-2 and survivin protein, and facilitating Bax protein expression. Detection of MG3 level in clinic in laryngeal cancer patients may provide valuable evaluation on prognosis from gene and protein aspects [22]. Further indepth investigation may provide better choice for the laryngeal cancer treatment.

### Acknowledgements

This work was supported by the National Natural Science Foundation of Zhejiang province, China (Y2100578 and Y2090486); Medical and health research project of Zhejiang Province, China (2017RC011) and the Development project of science and Technology of Hangzhou, China (20110833B09).

#### Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xuehua Zhou, Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Hangzhou Normal University, 126 Wenzhou Road, Hangzhou, Zhejiang, China. Tel:

+86-571-88303410; Fax: +86-571-88303410; E-mail: xuehuazhou22@163.com

#### References

- [1] Psyrri A, Kotoula V, Fountzilas E, Alexopoulou Z, Bobos M, Televantou D, Karayannopoulou G, Krikelis D, Markou K, Karasmanis I, Angouridakis N, Kalogeras KT, Nikolaou A, Fountzilas G. Prognostic significance of the Wnt pathway in squamous cell laryngeal cancer. Oral Oncol 2014; 50: 298-305.
- [2] Rosso M, Kraljik N, Mihaljevic I, Siric L, Sos D, Vranjes Z. Epidemiology of laryngeal cancer in Osijek-Baranja County (eastern Croatia). Coll Antropol 2012; 36 Suppl 2: 107-110.
- [3] Khaitan D, Dinger ME, Mazar J, Crawford J, Smith MA, Mattick JS, Perera RJ. The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res 2011; 71: 3852-3862.
- [4] Yang F, Zhang L, Huo XS, Yuan JH, Xu D, Yuan SX, Zhu N, Zhou WP, Yang GS, Wang YZ, Shang JL, Gao CF, Zhang FR, Wang F, Sun SH. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 2011; 54: 1679-1689.
- [5] Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y, Wei M, Chen J, Gao X, Xu C, Mao JH, Sun Y. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol Oncol 2013; 31: 1117-1123.
- [6] Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, Li X. Long non-coding RNA UCA1a(CUDR) promotes proliferation and tumorigenesis of bladder cancer. Int J Oncol 2012; 41: 276-284.
- [7] Marques AC, Ponting CP. Catalogues of mammalian long noncoding RNAs: modest conservation and incompleteness. Genome Biol 2009; 10: R124.
- [8] Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 2009; 23: 1494-1504.
- [9] Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-641.
- [10] Flintoft L. Non-coding RNA: structure and function for IncRNAs. Nat Rev Genet 2013; 14: 598.
- [11] He Y, Meng XM, Huang C, Wu BM, Zhang L, Lv XW, Li J. Long noncoding RNAs: novel insights into hepatocelluar carcinoma. Cancer Lett 2014; 344: 20-27.

- [12] Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, Xie WP, Hou YY. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer 2013; 13: 461.
- [13] Qin R, Chen Z, Ding Y, Hao J, Hu J, Guo F. Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. Neoplasma 2013; 60: 486-492.
- [14] Sun M, Xia R, Jin F, Xu T, Liu Z, De W, Liu X. Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 2014; 35: 1065-1073.
- [15] Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W, Chen J. Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/ miR-449a. Oncotarget 2014; 5: 2276-2292.
- [16] Bentzen SM. Prognostic factor studies in oncology: osteosarcoma as a clinical example. Int J Radiat Oncol Biol Phys 2001; 49: 513-518.
- [17] Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, Tridandapani S, Anant S, Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007; 6: 178-184.
- [18] Rosenfield RL. The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 2015; 136: 1154-1165.
- [19] Gougeon A. Human ovarian follicular development: from activation of resting follicles to preovulatory maturation. Ann Endocrinol (Paris) 2010; 71: 132-143.
- [20] Luanpitpong S, Chanvorachote P, Stehlik C, Tse W, Callery PS, Wang L, Rojanasakul Y. Regulation of apoptosis by Bcl-2 cysteine oxidation in human lung epithelial cells. Mol Biol Cell 2013; 24: 858-869.
- [21] Bates GW Jr, Propst AM. Polycystic ovarian syndrome management options. Obstet Gynecol Clin North Am 2012; 39: 495-506.
- [22] Jia LF, Wei SB, Gan YH, Guo Y, Gong K, Mitchelson K, Cheng J, Yu GY. Expression, regulation and roles of miR-26a and MEG3 in tongue squamous cell carcinoma. Int J Cancer 2014; 135: 2282-2293.